Jean‐François Baladi

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs

Theodore Darkow, Henry J. Henk, Simu K. Thomas et al. · PharmacoEconomics · 2007 · 266 citations

Health Policy, Treatment And Prevention, Patient Safety +8

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia

Maria Domenica Cappellini, Mohamed Béjaoui, Leyla Ağaoğlu et al. · Clinical Therapeutics · 2007 · 118 citations

Anemia, Patient-reported Outcomes, Iron Metabolism +4

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients

Thomas E. Delea, Oleg Sofrygin, Simu K. Thomas et al. · PharmacoEconomics · 2007 · 78 citations

Infusional Deferoxamine, Translational Medicine, Medicine +7

Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload

Krista Payne, Diana Rofail, Jean‐François Baladi et al. · Advances in Therapy · 2008 · 72 citations

Health Economics, Health Policy, Iron Metabolism +4

ECONOMIC ANALYSIS OF BASILIXIMAB IN RENAL TRANSPLANTATION1

Paul Keown, Robert Balshaw, Hans Krueger et al. · Transplantation · 2001 · 61 citations